CoChat

Randomized, placebo‐controlled, double‐blind glycemic control trial of novel sodium‐dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus

Open access
Kashiwagi, Atsunori, Kazuta, Kenichi, Yoshida, Satoshi, Nagase, Itsuro · 2014 · Journal of Diabetes Investigation
Cited by 101

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Aims/Introduction: In the present dose–response study, we evaluated the efficacy and safety of ipragliflozin (ASP 1941), a novel and selective inhibitor of sodium‐dependent glucose cotransporter 2, in Japanese patients with type 2 diabetes mellitus. Materials and Methods: A total of 361 patients from 39 Japanese centers were randomized to receive either once‐daily oral ipragliflozin (12.5, 25, 50 or 100 mg) or a placebo for 12 weeks. Results: All ipragliflozin‐treated groups had clinically significant, dose‐dependent decreases in glycated hemoglobin (H b A 1c) and fasting plasma glucose levels compared with placebo‐treated groups. The adjusted mean difference in H b A 1c change from baseline to the end of treatment between the placebo and 12.5, 25, 50, and 100 mg ipragliflozin groups were −0.61%, −0.97%, −1.29%, and −1.31%, respectively (P < 0.001). Reductions in H b A 1c levels were similar between obese and non‐obese patients, and were larger in patients with baseline H b A 1c ≥8.4% than in those with H b A 1c <8.4%. Furthermore, bodyweight significantly (P < 0.001) and dose‐dependently decreased among ipragliflozin‐treated groups compared with the placebo group. The incidence of adverse events was similar across all groups. However, mild increases in hematocrit and blood urea nitrogen were found in ipragliflozin treated groups. Conclusions: Once‐daily administration of ipragliflozin was dose‐dependently effective in glycemic control without major adverse effects. Ipragliflozin was equally effective between obese and non‐obese patients, and led to weight loss in both groups. Ipragliflozin was safe and well‐tolerated in J apanese patients with type 2 diabetes mellitus. This trial was registered with ClinicalTrials.gov (no. NCT 00621868).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jdi.12156

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 101

Metadata

Authors
Kashiwagi, A., Kazuta, K., Yoshida, S., & Nagase, I.
Venue
Journal of Diabetes Investigation
Publisher
Wiley
Published
2013-11-28
Volume
5
Issue
4
Pages
382-391
ISSN
  • 2040-1116 (ISSN-L)
  • 2040-1124
OpenAlex
W2093133419
Cited by
101
References
4
FWCI
7.55
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized, placebo‐controlled, double‐blind glycemic control trial of novel sodium‐dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1111/jdi.12156
The paper
Kashiwagi, A., Kazuta, K., Yoshida, S., & Nagase, I. (2014). Randomized, placebo‐controlled, double‐blind glycemic control trial of novel sodium‐dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.12156

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.